Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 85%
filed 2026-09-10
Nu Holdings announced the commencement of U.S. operations on September 10, 2026, with launch of a full suite of financial products including deposit accounts, money transfers, credit cards, and a new multi-currency digital account (Nu Global). This represents a material operational and strategic milestone — entry into a major new market with multiple product lines — but does not fit the specific event categories (not M&A, not a financial result, not a governance change). The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's growth trajectory and market reach.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
Item 8.01
CervoMed announced that initial Phase 2a clinical trial results for neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted for a late-breaking oral presentation at the ISFTD 2026 Annual Meeting in October 2026, with 12-week biomarker data from at least 22 participants to be highlighted. This represents a material clinical development milestone for the company's lead drug candidate, signaling progress in the drug development pipeline and affecting investor assessment of the company's prospects toward potential regulatory approval and commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-10
EX-99.1
This press release announces the delivery of a new LPG bobtail tanker to Al Shola Gas (Fusion Fuel's indirect subsidiary) expected to generate approximately $1.6 million in annual recurring revenue, along with the company's receipt of a Dubai Petroleum Products Permit. The disclosure describes a material operational and strategic expansion—fleet growth from 52 to 53 vehicles, incremental revenue-generating capacity, and regulatory authorization strengthening competitive positioning in the UAE LPG market. While the event involves capital deployment and revenue generation, it is fundamentally an operational business milestone (asset acquisition and regulatory approval) rather than a discrete financial event (debt issuance, equity offering, or M&A transaction) or a periodic financial report.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-10
EX-99.1
This press release announces results from laboratory-scale metallurgical testwork on IMC's Itarantim rare earth project, demonstrating high terbium recoveries (up to 95.2%) and successful production of mixed rare earth carbonate. The disclosure is a material operational milestone for an exploration and development company—it reports positive technical progress on its principal project that would inform investor assessment of project viability and development pathway. While not a discrete M&A, financing, or governance event, it is a significant operational and technical achievement that advances the company's core business objective and warrants classification as an operational event rather than a routine administrative disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-10
The filing discloses two material agreements entered into on September 9, 2026: (1) a Subscription Agreement granting TAP Real Estate a 2% equity interest in Alpenhaus Resort, LLC in exchange for transferring an option to purchase the Zermatt Resort, and (2) a Technology Services Agreement providing digital infrastructure services to the resort for $60,000 upfront plus $6,000 monthly, with exclusive tokenization rights. While Item 1.01 is titled "Entry into a Material Definitive Agreement," the substance centers on a strategic business partnership and technology services engagement rather than a traditional M&A transaction, debt issuance, or other specifically-defined event type. The equity stake and recurring revenue model represent a material operational and strategic development for the company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-10
EX-99.1
This is a mineral exploration progress report announcing drilling results from the Rift Rare Earth Project. The exhibit discloses assay results from five drillholes (RIFT26-015 through RIFT26-019) showing rare earth oxide (REO) mineralization intervals, expansion of the Trinity Zone mineralization footprint to 500 m strike length and 300 m down-dip, and confirmation of high-grade REO continuity. The CEO states the company remains "on track for an inaugural mineral resource estimate in Q1 2027." This is a material operational/exploration milestone for a mineral exploration company, as it demonstrates progress toward resource definition and supports the strategic value of the flagship project, but it does not fit the discrete event categories (not M&A, not an earnings release, not a restatement or going-concern issue). The disclosure would affect a reasonable investor's assessment of the company's exploration success and project advancement.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
FingerMotion announced a non-binding memorandum of understanding with Lyken AI Computing Inc. and BlueFlare Energy Solutions Inc. to establish a demand-to-capacity matching framework for AI and high-performance computing infrastructure in Western Canada. While the MOU is explicitly non-binding and non-exclusive with no pricing or minimum commitments, it represents a material strategic partnership and operational development initiative that operationalizes the company's AI infrastructure strategy and corridor development program, disclosed under Item 8.01 (Other Events).
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
Item 8.01
The filing discloses preliminary August 2026 AUM of $183.5 billion and a material client diversification event: a long-standing sub-advisory client is transitioning from single-manager to multi-manager structure, resulting in an anticipated $6 billion rebalancing from the Global Value strategy. This is an operational/strategic business event affecting the firm's asset base and revenue, but does not fit the specific categories of earnings release (no full financial results), material_litigation, or other named types. The disclosure is material to investors assessing the registrant's business performance and client relationships.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-10
Guardian Metal announced a collaboration agreement with Oritain Global to develop tungsten origin verification and forensic fingerprinting capabilities. This is a material operational/strategic partnership that supports the company's core business mission to establish a verifiable U.S. tungsten supply chain, particularly timely given incoming U.S. defense procurement restrictions (Section 854 NDAA effective January 1, 2027) and Executive Order 14415 mandating supply chain traceability. While not a discrete M&A transaction, the agreement represents a significant strategic milestone that would affect investor assessment of the company's competitive positioning and ability to meet emerging regulatory requirements for domestic tungsten sourcing.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-10
GSK announced Japan's Ministry of Health, Labour and Welfare approval of a prefilled syringe presentation of Shingrix (Recombinant Zoster Vaccine). This is a regulatory milestone and product formulation approval that expands the commercial availability of an existing vaccine in a major market. While not a discrete M&A, earnings event, or executive change, it represents a material operational and commercial development—a new product presentation launch in Japan following earlier US and European launches—that would affect a reasonable investor's assessment of GSK's vaccine portfolio expansion and market reach.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
Item 1.01
DarkPulse entered into an exclusive patent license agreement with the U.S. Air Force on September 1, 2026, granting rights to six issued U.S. patents covering satellite power sharing, satellite communications, and laser-generation technologies. While Item 1.01 typically covers M&A activity, this is a material strategic partnership and technology licensing arrangement rather than an acquisition or change of control. The agreement includes significant economic terms (5% running royalty, minimum annual royalties escalating to $400,000+, and development milestones), making it a material operational and commercial event that would affect investor assessment of the company's growth prospects and revenue potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-10
EX-99.1
RYET announced entry into a memorandum of understanding with Changan Anyi and Intersect to develop an automotive and NEV institute in Saudi Arabia. This is a material strategic partnership and operational initiative that advances the Company's international education expansion strategy (Formind), combining industry expertise with institutional education delivery. While not a discrete M&A transaction, the MOU represents a significant operational and commercial development that would affect a reasonable investor's assessment of the Company's growth trajectory and international presence.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-10
EX-99.1
NuRAN announces entry into a new industry vertical—maritime private networks—through a pilot engagement with a fleet management company that could scale to up to 1,000 ships. This represents a material strategic expansion into an adjacent market leveraging the company's existing technology platform. While not a discrete M&A transaction, partnership, or contract award with binding terms, the pilot represents a significant operational and strategic initiative that would affect a reasonable investor's assessment of the company's growth prospects and diversification strategy.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
Item 1.01
Kala entered into an Exclusive Distribution and Reseller Agreement with Virotek on September 3, 2026, appointing Kala as the sole and exclusive distributor of a genetic testing and screening program for ophthalmology in the United States for five years. While this is a material commercial partnership with defined revenue-sharing terms (50/50 net profit split), right of first refusal on related products, and conditional exclusivity tied to a milestone, it does not constitute a merger, acquisition, or change of control (ma_activity), nor does it fit other specific financial or governance categories. This is a material operational/strategic partnership that would affect investor assessment of the company's growth prospects and revenue streams.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
Item 7.01
Core Scientific discloses regulatory approvals and status updates for electrical power allocations across three Texas data center sites (Denton, Pecos, and Hunt) from ERCOT. This is an operational/strategic milestone regarding infrastructure capacity and regulatory clearance for the company's data center expansion plans, which would materially affect investor assessment of the company's ability to execute its growth strategy. The disclosure does not fit a more specific category but is clearly operational in nature.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-10
Item 7.01
This Item 7.01 disclosure is a business update providing portfolio performance metrics, capital flows, and operational highlights for TPG Twin Brook Capital Income Fund. The filing reports 9.8% annualized total return since inception, $4.8 billion portfolio diversification across 287 positions, capital inflows of $128 million (July-September 2026), and strong liquidity of $1.1 billion. While the disclosure includes financial metrics (returns, NAV, distributions), it is fundamentally an operational and strategic update about fund performance and positioning rather than a discrete financial event like earnings release, debt issuance, or material impairment. The material nature stems from the comprehensive performance and liquidity information that would inform investor decisions about the fund.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-10
Cadeler announces an upward revision of its 2026 full-year revenue and EBITDA guidance, reflecting the impact of its acquisition of Menck completed on 11 August 2026. While the guidance revision itself is material to investors, the core disclosure is the company's updated outlook incorporating a recently completed acquisition. This is best classified as an operational event reflecting the strategic acquisition and its financial impact, rather than as a discrete M&A event (which would apply to the acquisition announcement itself) or an earnings release (which would be quarterly/annual results). The acquisition is mentioned as context for the guidance update, not as the primary disclosure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-10
Item 7.01
Ionic Digital announced that ERCOT has provisionally classified its remaining 466 MW energization request for the Ward County campus as Base Load in the Batch Zero process. This is a material operational and regulatory milestone for the company's data center infrastructure development strategy, as it represents progress toward the full 700 MW capacity target at the campus. The event is clearly operational (relating to the company's core business of HPC and data center infrastructure) but does not fit a specific named category; it is a regulatory/permitting milestone rather than a contract, partnership, or restructuring.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
NN Inc. posted an investor presentation to its website for use at the Lake Street Capital Markets Investor Conference on September 10, 2026. The presentation discloses material operational and strategic updates including: raised 2026 guidance (net sales to $470M, adjusted EBITDA to $60M), significant new business wins ($100M in 2026 guidance), expansion into AI data center liquid cooling, entry into Tier 1 defense weapons business, and medical device wins. While the disclosure mechanism is a Regulation FD presentation rather than a traditional earnings release or specific operational event, the content reflects material strategic progress across the company's five-pillar growth program and would affect a reasonable investor's assessment of NN's business trajectory and market opportunities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
Flotek issued a press release on September 9, 2026, providing an updated guidance increase for full-year 2026 revenue (to $360–$370 million) and Adjusted EBITDA (to $50–$54 million), representing 54% and 58% growth respectively versus 2025. While guidance updates are forward-looking disclosures typically furnished under Item 7.01 (Regulation FD Disclosure), this disclosure centers on operational and strategic performance metrics—strong international chemistry sales growth, data analytics segment expansion, and execution of corporate strategy—rather than a discrete financial event (earnings release, debt issuance, M&A, etc.). The guidance reflects sustained business momentum and market demand, making it an operational/strategic update rather than a formal earnings release or other specific financial event type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
Sysco disclosed reaffirmation of fiscal 2027 guidance, introduction of a $500 million multi-year AI-powered efficiency improvement program, and raising of mid-term financial targets for fiscal 2028-2029. While the press release includes forward-looking financial guidance, the core material event is the announcement of a significant operational transformation initiative (the AI efficiency program) and strategic cost-out efforts, which is operational in nature rather than a pure earnings release or financial guidance update. The program targets structural cost reduction across supply chain, automation, indirect spend, and customer experience over three years.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
This news release announces positive exploration drill results at First Majestic's San Dimas Silver/Gold Mine in Mexico, including high-grade silver and gold intercepts across multiple vein systems and expansion of the exploration footprint. The company reports completion of approximately 89,000 metres of a planned 117,000-metre 2026 exploration program, with results supporting near-mine Mineral Resource conversion and growth opportunities. While not a discrete M&A, financing, or governance event, the announcement of a major exploration program's progress with material drill results that support future resource growth is operationally significant to a mining company's investors and would affect their assessment of the registrant's prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
The exhibit announces initiation of a Phase 1 clinical trial for JST-018, an investigational monoclonal antibody cocktail developed under a U.S. Department of War contract. This represents a material operational and clinical milestone for Evotec's biologics subsidiary, demonstrating advancement of a government-funded biodefense program from development through manufacturing to first-in-human studies. While not a discrete M&A, financing, or governance event, the clinical advancement of a material program under a contract with combined potential value of up to $123.9 million would affect a reasonable investor's assessment of the company's pipeline and operational capabilities.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
Adagene announced achievement of a preclinical milestone in its collaboration with Exelixis, triggering a $2.0 million milestone payment and selection of additional SAFEbody ADC candidates. This is a material operational/partnership milestone that demonstrates progress in a strategic collaboration and generates near-term cash, but does not fit the discrete event categories (not M&A, not a discrete financing, not a clinical trial result announcement). The milestone achievement and associated payment represent meaningful progress in the company's pipeline development strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
ProQR announced the first participant dosed in the Phase 1 clinical trial of AX-0811, a next-generation RNA editing oligonucleotide for cholestatic liver diseases. This represents a material clinical development milestone—advancement of a lead pipeline program into human testing—that would affect a reasonable investor's assessment of the company's progress and pipeline execution. The announcement also includes expected timing for Phase 1 target engagement data (early January 2027) and details of an investor educational event. This is a discrete operational/clinical milestone rather than a periodic report, earnings release, or other named event type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
MetaVia disclosed preclinical study results for DA-1726 demonstrating tissue distribution and retention patterns that support the drug's once-weekly dosing profile and mechanism for obesity treatment. This material clinical milestone provides mechanistic rationale for the company's lead product candidate and supports ongoing Phase 1 development.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
Biophytis announced a protocol amendment to its Phase 2 OBA clinical study, expanding the evaluation of BIO101 to assess its potential to limit weight regain ("rebound effect") following semaglutide discontinuation. The amendment has been submitted to ANVISA (Brazil) with planned submissions to the FDA and EMA. This represents a material expansion of the clinical development scope for the company's lead drug candidate in obesity, a key indication under its licensing agreement with Blanver (worth up to €108 million). The amendment is operational and strategic in nature—affecting the clinical trial design and regulatory pathway—rather than a discrete event type like M&A, litigation, or financial reporting.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
Middleby announced the discontinuation of its Brewing & Distilling Solutions Group business, representing $24 million in 2025 net sales with a $9 million adjusted EBITDA loss. While the company states the discontinuation is "immaterial to its 2026 financial guidance," the decision reflects a material operational restructuring and business simplification initiative that would affect a reasonable investor's assessment of the company's portfolio and strategic direction. This is an operational/strategic business event rather than a workforce reduction (no layoff details provided) or financial impairment (the $5 million impairment is already reflected in the adjusted EBITDA calculation).
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-09
Item 8.01
Opus Genetics disclosed positive interim clinical trial data from Cohort 1 of its Phase 1/2 BIRD-1 trial of OPGx-BEST1, demonstrating safety (no serious adverse events), efficacy (visual function improvements in all five participants, structural improvements in four), and successful FDA alignment on pivotal trial endpoints. The company is advancing to Cohort 2, representing a material clinical and regulatory milestone for the drug candidate's development trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
Elevra Lithium disclosed results of a Pre-Feasibility Study for a staged brownfield expansion of its North American Lithium operation in Québec, confirming plans to increase annual spodumene concentrate production from 199 ktpa to 373 ktpa, reduce unit operating costs from C$1,048/t to C$851/t, and generate an incremental post-tax NPV of C$943M (US$699M) with a 49.9% IRR.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
The press release discloses continued operational development activity in the Permian Basin, including nine producing wells, a tenth well in completion, and future drilling plans with estimated drilling locations. This is a material operational and strategic update regarding the company's core E&P business development, but does not fit the specific categories of earnings release (no financial results disclosed), material_litigation, cybersecurity_incident, or other named event types. The disclosure of well performance metrics, production rates, and development outlook is clearly operational in nature and would affect a reasonable investor's assessment of the company's asset quality and growth trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
This press release announces significant progress on the Kilbourne Graphite Project's permitting milestones, including completion of the USACE public comment stage for the Section 404 permit, advancement of cultural resources and Endangered Species Act reviews, and submission of the Joint Application to New York State DEC. The disclosure describes operational and regulatory progress toward commercial production in 2028, design optimizations reducing environmental footprint by 50%, and federal support including $120 million in EXIM financing. This is a material operational/strategic milestone for a development-stage project, not a discrete event fitting the standard taxonomy categories (not M&A, not a financial result, not an executive change, not a covenant breach or going concern).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
Gilat announced receipt of a $32 million order from the U.S. Department of War for DKET Systems with deliveries over 12 months. This is a material contract award that represents significant expansion of Gilat DataPath's defense business and reinforces the company's position in U.S. mission-critical communications programs. While not a discrete M&A transaction, it is a substantial operational/commercial milestone that would affect a reasonable investor's assessment of the company's growth trajectory and defense-sector revenue.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
Ituran announced a multi-year contract award with the Israeli Ministry of Transport valued at over NIS 21 million (approximately US$7 million) for a Big Data traffic-monitoring SaaS platform. This represents a new recurring revenue stream and validates the company's Big Data platform beyond its core telematics services. While not a discrete M&A transaction, debt issuance, or earnings release, this material contract award represents a significant operational and strategic milestone that would affect a reasonable investor's assessment of the company's growth prospects and diversification into new markets.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
PRF Technologies announced its plan to establish GridFeed as a standalone, wholly owned subsidiary to pursue strategic alliances and commercialization of its AI-driven renewable energy trading platform. This is a material operational and strategic restructuring—the company is creating a dedicated vehicle for GridFeed to attract direct investment, partnerships, and commercial opportunities. While the subsidiary remains wholly owned (not a spin-off or divestiture), the structural change and strategic intent to enable external partnerships and investment represent a significant operational decision that would affect a reasonable investor's assessment of the company's growth strategy and capital structure.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
ParaZero announced a Memorandum of Understanding (MOU) with a Tier-1 European Defense Company to integrate its DefendAir Counter-UAS system into armored vehicles, with an initial purchase order already placed and planned on-site engineering support. This is a material strategic partnership and commercial milestone for the company's core DefendAir product line, representing advancement toward platform-level integration with a major defense manufacturer. While not a completed acquisition or M&A transaction (which would be `ma_activity`), this represents a significant operational and commercial development that would affect a reasonable investor's assessment of the company's market traction and revenue prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.2
XORTX Therapeutics re-engaged IR Agency LLC for investor relations and marketing services following completion of its voluntary delisting from the TSX Venture Exchange, under a revised consulting agreement valued at US$2.5 million over three months.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
Baker Hughes disclosed that CEO Lorenzo Simonelli will present at the Barclays 2026 CEO Energy-Power Conference on September 9, 2026, discussing the company's positioning and "updated fiscal-year 2026 financial guidance incorporating Chart." The presentation covers the integration of the recent Chart Industries acquisition, synergy execution, and strategic positioning across energy, industrial, and infrastructure markets. While the disclosure includes forward-looking guidance and non-GAAP measures, the core event is a strategic business presentation and guidance update tied to a material acquisition integration, which is operational in nature rather than a discrete financial event like earnings release or debt issuance.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
SK hynix is responding to a Korea Exchange disclosure inquiry regarding media reports of a potential sale of an ownership stake in its Chongqing packaging plant, valued at approximately Won 4 trillion. While the Company states no matters have been determined, the disclosure of a material strategic review of a significant asset (a packaging plant valued at ~$3 billion USD equivalent) constitutes an operational event that would affect a reasonable investor's assessment of the registrant's capital allocation and business strategy. The materiality and scale of the potential transaction, combined with the Company's acknowledgment of reviewing "various measures to strengthen competitiveness," supports classification as a material operational matter, though the lack of definitive action prevents classification as a completed M&A event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-09
Item 8.01
Kura Oncology formed a wholly owned subsidiary (Caspian Therapeutics) and contributed material intellectual property and assets (including compound KO-7246 and menin inhibitor patents) in exchange for equity ownership, while retaining ~49.2% of Caspian post-financing. This represents a significant strategic restructuring and spin-out of a business line focused on cardiometabolic diseases, coupled with a $50 million Series A financing in which the parent invested $4.3 million. While this involves subsidiary financing and asset contribution, it is primarily a strategic operational and organizational event rather than a traditional M&A transaction, debt issuance, or equity dilution of the parent company itself.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-09
Item 8.01
Tyra announced initial Phase 2 clinical trial results for dabogratinib in FGFR3-altered bladder cancer (SURF302), demonstrating favorable safety and efficacy outcomes (79% ORR at 60 mg QD, no Grade 4/5 adverse events) and identifying the dose for planned Phase 3 registrational studies. This is a material clinical development milestone for a biopharmaceutical company's lead program, affecting investor assessment of pipeline progress and regulatory pathway, but does not fit the earnings_release category (which typically applies to financial results disclosures) nor any other specific taxonomy type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-09
Item 8.01
Pyxis Oncology disclosed updated Phase 1 clinical trial data for its lead candidate MICVO in head and neck cancer, demonstrating efficacy results (36% cORR, 94% DCR, 6.2-month mPFS, 79% 12-month OS) and a manageable safety profile with no new safety signals. The company plans to initiate a Phase 3 pivotal trial in mid-2027 with FDA/EMA alignment on trial design, representing a material de-risking milestone for the company's lead program.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
The disclosure announces project updates across Contango's exploration and development portfolio, including completion of drilling programs at Lucky Shot, Johnson Tract, and Kitsault Valley, as well as production updates from the Manh Choh mine. While these are operational milestones and exploration progress updates rather than a specific named event type (not M&A, not a material impairment, not a workforce reduction), they represent material operational and strategic developments that would affect a reasonable investor's assessment of the company's execution capability and project advancement. The CEO's statement emphasizes delivery "on time and on budget" across multiple sites, and the Johnson Tract section references a post-tax NPV of $615.4 million, indicating material value creation potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
The filing discloses Tenax's presentation of Phase 3 LEVEL clinical trial results for levosimendag (TNX-103) in pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF) at the Cantor Global Healthcare Conference on September 9, 2026. While the primary endpoint (6-minute walk distance) did not reach statistical significance (p=0.63), the presentation emphasizes post-hoc subgroup analyses showing meaningful treatment effects in patients with lower baseline exercise capacity and discusses strategic implications for the LEVEL-2 trial design. This is a material clinical development milestone that would affect investor assessment of the company's lead product candidate, though it is disclosed under Item 7.01 (Regulation FD Disclosure) rather than a dedicated clinical results item.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
The 6-K discloses Week 52 data from the reACHin Trial sentinel cohort showing that TransCon CNP (navepegritide) achieved stabilization or improvement in foramen magnum stenosis and linear growth benefits in infants with achondroplasia. This is a material clinical trial milestone for a pivotal Phase 2 program, but it is not a discrete earnings release, M&A activity, executive change, or other specifically-named event type. The disclosure represents a significant operational/clinical development milestone that would affect investor assessment of the company's pipeline progress and regulatory prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-09
The filing discloses a stockholder letter from CEO Matt Fisch highlighting multiple operational and commercial achievements: a multi-million-dollar NASA-backed lunar contract with Lunar Outpost, new sports analytics development contract with Alive3D, appointment of Chief Revenue Officer Laura Wrisley, record commercial engagement (25 customers, 19% increase), and significant revenue growth (9x year-over-year, 4 consecutive quarters of growth). While the letter emphasizes commercial momentum and new market expansion, it does not fit neatly into specific event categories—it is neither a discrete M&A transaction, earnings release with formal results, nor a single executive appointment, but rather a comprehensive operational update covering multiple business developments and strategic progress. The material nature is evident from the record pipeline, revenue growth metrics, and expansion into new verticals (space mobility, sports analytics).
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
This press release announces the publication of a peer-reviewed case report describing clinical improvement in a decompensated cirrhosis patient treated with Namodenoson, one of Can-Fite's lead drug candidates. The patient experienced resolution of ascites, regression of esophageal varices, and remained stable for 28 months before successful liver transplantation. While this is a single-patient case report rather than a formal clinical trial result, it represents a material operational/clinical milestone for the company's drug development pipeline, supporting further evaluation of Namodenoson in advanced liver disease and potentially influencing investor assessment of the company's clinical progress.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
The filing discloses multiple operational and clinical milestones for a clinical-stage biopharmaceutical company: commencement of patient dosing in the DReAMzz Phase 2 study of IHL-42X for obstructive sleep apnea, grant of a U.S. composition patent extending to 2040, and a strong cash position of approximately $70 million with no debt. While the press release covers clinical progress, intellectual property, and financial position, the core event is the advancement of the company's drug development pipeline and operational progress rather than a specific financial transaction, governance change, or other named event type. This is material to investors assessing the registrant's clinical and operational trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
This is an announcement of positive Phase 1 clinical trial data for RAD301, a radiopharmaceutical candidate in development for pancreatic cancer. The disclosure reports favorable safety, biodistribution, and significant tumor uptake results that support advancement to Phase 2 development. While this is a material clinical milestone for a clinical-stage biopharmaceutical company, it does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). It is a material operational/strategic milestone—a positive clinical development outcome that would affect investor assessment of the company's pipeline progress and value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
This press release announces a non-binding Memorandum of Understanding between Rice Robotics AGI (Mint's majority-owned joint venture) and Edvance Innovation Limited to establish a strategic distribution partnership for the MENA education robotics market. The MOU outlines a commercial goal of deploying 3,000 units over 36 months with a first purchase order of 50 units targeted by November 2026. While this represents a material strategic expansion into a new geographic market and vertical (education), it is non-binding and contingent on execution of definitive agreements, making it an operational/strategic partnership announcement rather than a completed M&A transaction or binding commitment.
View raw filing on EDGAR →